Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Prostatic Neoplasms × Buserelin × Clear all

Phase

Status

Completed 5 Active not recruiting 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1

Interventions

Docetaxel 49 Prednisone 32 Leuprolide 21 enzalutamide 20 Magnetic Resonance Spectroscopy 16 Abiraterone Acetate 16 bicalutamide 15 Goserelin 13 Radiotherapy 12 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10 abiraterone 10 cabazitaxel 8 Radiotherapy, Intensity-Modulated 8 Gonadotropin-Releasing Hormone 8 Cyclophosphamide 8 Androgen Antagonists 8 olaparib 7 gallium 68 PSMA-11 7 apalutamide 7 Metformin 7 Ketoconazole 7 Doxorubicin 7 luprolide acetate gel depot 6 Estramustine 6 pembrolizumab 5 cabozantinib 5 Zoledronic Acid 5 Radiosurgery 5 Radiation 5 Mitoxantrone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00651326 2023-08-04

DART

Canadian Cancer Trials Group

Phase 3 Terminated

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡